Probiotics in the treatment of the liver diseases

Journal of the American College of Nutrition

Volumn 31, Issue 1, 2012, Pages 14-23

  Kirpich, Irina A ^a,c   McClain, Craig J ^a,b,c,d  

^a Div of Gastroenterology/Hepatology   (United States)

^b Department of Pharmacology and Toxicology ^*  (United States)

^c University of Louisville School of Medicine   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Microflora; Nonalcoholic and alcoholic liver disease; Probiotics

Indexed keywords

PREBIOTIC AGENT; PROBIOTIC AGENT; SYMBIOTICS; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; ALCOHOL LIVER DISEASE; ARTICLE; HUMAN; INFLAMMATION; INTESTINE; INTESTINE FLORA; LIVER DISEASE; LIVER INJURY; MOLECULAR DYNAMICS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS;

ANIMALS; ENDOTOXEMIA; FATTY LIVER; HUMANS; INTESTINES; LIVER DISEASES, ALCOHOLIC; MODELS, ANIMAL; PREBIOTICS; PROBIOTICS; SYMBIOSIS;

EID: 84864950939     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2012.10720004     Document Type: Article

References (76)

1. PurohitV, BodeJC, BodeC, BrennerDA, ChoudhryMA, HamiltonF, KangYJ, KeshavarzianA, RaoR, SartorRB, SwansonC, TurnerJR: Alcohol, intestinal bacterial growth, intestinal permeability to endotoxin, and medical consequences: summary of a symposium. Alcohol42:349-361, 2008.
2. RaoRK, SethA, ShethP: Recent advances in alcoholic liver disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol286:G881-G884, 2004.
3. BrunP, CastagliuoloI, Di LeoV, BudaA, PinzaniM, PaluG, MartinesD: Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol292:G518-G525, 2007.
4. LeyRE, TurnbaughPJ, KleinS, GordonJI: Microbial ecology: human gut microbes associated with obesity. Nature 444:1022-1023, 2006.
5. XuJ, GordonJI: Honor thy symbionts. Proc Natl Acad Sci U S A100:10452-10459, 2003.
6. TurnbaughPJ, HamadyM, YatsunenkoT, CantarelBL, DuncanA, LeyRE, SoginML, JonesWJ, RoeBA, AffourtitJP, EgholmM, HenrissatB, HeathAC, KnightR, GordonJI: A core gut microbiome in obese and lean twins. Nature457:480-484, 2009.
7. FrankDN, St AmandAL, FeldmanRA, BoedekerEC, HarpazN, PaceNR: Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A104:13780-13785, 2007.
8. MencinA, KluweJ, SchwabeRF: Toll-like receptors as targets in chronic liver diseases. Gut58:704-720, 2009.
9. BackhedF, DingH, WangT, HooperLV, KohGY, NagyA, SemenkovichCF, GordonJI: The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A101:15718-15723, 2004.
10. CaniPD, NeyrinckAM, FavaF, KnaufC, BurcelinRG, TuohyKM, GibsonGR, DelzenneNM: Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia50:2374-2383, 2007.
11. CaniPD, AmarJ, IglesiasMA, PoggiM, KnaufC, BastelicaD, NeyrinckAM, FavaF, TuohyKM, ChaboC, WagetA, DelmeeE, CousinB, SulpiceT, ChamontinB, FerrieresJ, TantiJF, GibsonGR, CasteillaL, DelzenneNM, AlessiMC, BurcelinR: Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes56:1761-1772, 2007.
12. CopeK, RisbyT, DiehlAM: Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology119:1340-1347, 2000.
13. TurnbaughPJ, LeyRE, MahowaldMA, MagriniV, MardisER, GordonJI: An obesity-associated gut microbiome with increased capacity for energy harvest. Nature444:1027-1031, 2006.
14. LeyRE, BackhedF, TurnbaughP, LozuponeCA, KnightRD, GordonJI: Obesity alters gut microbial ecology. Proc Natl Acad Sci U S A102:11070-11075, 2005.
15. CaniPD, BibiloniR, KnaufC, WagetA, NeyrinckAM, DelzenneNM, BurcelinR: Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes57:1470-1481, 2008.
16. Kirpich IA, Feng W, Wang Y, Liu Y, Barker DF, Barve SS, McClain CJ: The type of dietary fat modulates intestinal tight junction integrity, gut permeability, and hepatic toll-like receptor expression in a mouse model of alcoholic liver disease. Alcohol Clin Exp Res 2011 Dec 7. doi: 10.1111/j.1530-0277.2011.01673. x. [Epub ahead of print]
17. LiS, WuWC, HeCY, HanZ, JinDY, WangL: Change of intestinal mucosa barrier function in the progress of non-alcoholic steatohepatitis in rats. World J Gastroenterol14:3254-3258, 2008.
18. WiggAJ, Roberts-ThomsonIC, DymockRB, McCarthyPJ, GroseRH, CumminsAG: The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut48:206-211, 2001.
19. FarhadiA, GundlapalliS, ShaikhM, FrantzidesC, HarrellL, KwasnyMM, KeshavarzianA: Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int28:1026-1033, 2008.
20. MieleL, ValenzaV, La TorreG, MontaltoM, CammarotaG, RicciR, MascianaR, ForgioneA, GabrieliML, PerottiG, VecchioFM, RapacciniG, GasbarriniG, DayCP, GriecoA: Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology49:1877-1887, 2009.
21. HarteAL, da SilvaNF, CreelySJ, McGeeKC, BillyardT, Youssef-ElabdEM, TripathiG, AshourE, AbdallaMS, SharadaHM, AminAI, BurtAD, KumarS, DayCP, McTernanPG: Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond)7:15, 2010.
22. NanjiAA, KhettryU, SadrzadehSM: Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med205:243-247, 1994.
23. AdachiY, MooreLE, BradfordBU, GaoW, ThurmanRG: Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology108:218-224, 1995.
24. FerrierL, BerardF, DebrauwerL, ChaboC, LangellaP, BuenoL, FioramontiJ: Impairment of the intestinal barrier by ethanol involves enteric microflora and mast cell activation in rodents. Am J Pathol168:1148-1154, 2006.
25. FukuiH, BraunerB, BodeJC, BodeC: Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol12:162-169, 1991.
26. ParlesakA, SchaferC, SchutzT, BodeJC, BodeC: Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcoholinduced liver disease. J Hepatol32:742-747, 2000.
27. BodeC, KuglerV, BodeJC: Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol4:8-14, 1987.
28. JokelainenK, ReinkeLA, NanjiAA: Nf-kappab activation is associated with free radical generation and endotoxemia and precedes pathological liver injury in experimental alcoholic liver disease. Cytokine16:36-39, 2001.
29. NanjiAA, JokelainenK, FotouhiniaM, RahemtullaA, ThomasP, TipoeGL, SuGL, DannenbergAJ: Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines. Am J Physiol Gastrointest Liver Physiol 281:G1348-G1356, 2001.
30. ZhongW, McClainCJ, CaveM, KangYJ, ZhouZ: The role of zinc deficiency in alcohol-induced intestinal barrier dysfunction. Am J Physiol Gastrointest Liver Physiol298:G625-G633, 2010.
31. BodeC, KolepkeR, SchaferK, BodeJC: Breath hydrogen excretion in patients with alcoholic liver disease—evidence of small intestinal bacterial overgrowth. Z Gastroenterol31:3-7, 1993.
32. MorencosFC, De Las Heras Castano G, Martin Ramos L, Lopez Arias MJ, Ledesma F, Pons Romero F: Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci40:1252-1256, 1995.
33. KirpichIA, SolovievaNV, LeikhterSN, ShidakovaNA, LebedevaOV, SidorovPI, BazhukovaTA, SolovievAG, BarveSS, McClainCJ, CaveM: Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol42:675-682, 2008.
34. YanAW, FoutsDE, BrandlJ, StarkelP, TorralbaM, SchottE, TsukamotoH, NelsonKE, BrennerDA, SchnablB: Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology53:96-105, 2011.
35. WangY, KirpichI, LiuY, MaZ, BarveS, McClainCJ, FengW: Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxia-inducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. Am J Pathol179:2866-2875, 2011.
36. MutluE, KeshavarzianA, EngenP, ForsythCB, SikaroodiM, GillevetP: Intestinal dysbiosis: a possible mechanism of alcoholinduced endotoxemia and alcoholic steatohepatitis in rats. Alcohol Clin Exp Res33:1836-1846, 2009.
37. BananA, ChoudharyS, ZhangY, FieldsJZ, KeshavarzianA: Ethanol-induced barrier dysfunction and its prevention by growth factors in human intestinal monolayers: evidence for oxidative and cytoskeletal mechanisms. J Pharmacol Exp Ther291:1075-1085, 1999.
38. KeshavarzianA, FieldsJZ, VaethJ, HolmesEW: The differing effects of acute and chronic alcohol on gastric and intestinal permeability. Am J Gastroenterol89:2205-2211, 1994.
39. MathurinP, DengQG, KeshavarzianA, ChoudharyS, HolmesEW, TsukamotoH: Exacerbation of alcoholic liver injury by enteral endotoxin in rats. Hepatology32:1008-1017, 2000.
40. TangY, BananA, ForsythCB, FieldsJZ, LauCK, ZhangLJ, KeshavarzianA: Effect of alcohol on miR-212 expression in intestinal epithelial cells and its potential role in alcoholic liver disease. Alcohol Clin Exp Res32:355-364, 2008.
41. TangY, ForsythCB, FarhadiA, RanganJ, JakateS, ShaikhM, BananA, FieldsJZ, KeshavarzianA: Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage. Alcohol Clin Exp Res33:1220-1230, 2009.
42. BananA, FieldsJZ, DeckerH, ZhangY, KeshavarzianA: Nitric oxide and its metabolites mediate ethanol-induced microtubule disruption and intestinal barrier dysfunction. J Pharmacol Exp Ther294:997-1008, 2000.
43. KeshavarzianA, JacynoM, UrbanG, WinshipD, FieldsJZ: The role of nitric oxide in ethanol-induced gastrointestinal dysfunction. Alcohol Clin Exp Res20:1618-1624, 1996.
44. FarhadiA, KeshavarzianA, RanjbaranZ, FieldsJZ, BananA: The role of protein kinase C isoforms in modulating injury and repair of the intestinal barrier. J Pharmacol Exp Ther316:1-7, 2006.
45. ZhongW, ZhaoY, McClainCJ, KangYJ, ZhouZ: Inactivation of hepatocyte nuclear factor-4falphag mediates alcohol-induced downregulation of intestinal tight junction proteins. Am J Physiol Gastrointest Liver Physiol299:G643-G651, 2010.
46. AminPB, DiebelLN, LiberatiDM: Dose-dependent effect of ethanol andE. coli on gut permeability and cytokine production. J Surg Res157:187-192, 2009.
47. MandrekarP, SzaboG: Signalling pathways in alcohol-induced liver inflammation. J Hepatol50:1258-1266, 2009.
48. McClainCJ, BarveS, DeaciucI, HillDB: Tumor necrosis factor and alcoholic liver disease. Alcohol Clin Exp Res22:S248-S252, 1998.
49. GustotT, LemmersA, MorenoC, NagyN, QuertinmontE, NicaiseC, FranchimontD, LouisH, DeviereJ, Le MoineO: Differential liver sensitization to toll-like receptor pathways in mice with alcoholic fatty liver. Hepatology43:989-1000, 2006.
50. MetchnikoffE: “The Prolongation of Life: Optimistic Studies.” New York: Springer Publishing Company, Inc, 2004.
51. ShermanPM, OssaJC, Johnson-HenryK: Unraveling mechanisms of action of probiotics. Nutr Clin Pract24:10-14, 2009.
52. NgSC, HartAL, KammMA, StaggAJ, KnightSC: Mechanisms of action of probiotics: recent advances. Inflamm Bowel Dis15:300-310, 2009.
53. GibsonGR, RoberfroidMB: Dietary modulation of the human colonic microbiota: introducing the concept of prebiotics. J Nutr125:1401-1412, 1995.
54. DelzenneNM, DaubioulC, NeyrinckA, LasaM, TaperHS: Inulin and oligofructose modulate lipid metabolism in animals: review of biochemical events and future prospects. Br J Nutr87(suppl 2):S255-S259, 2002.
55. MaX HJ, LiZ: Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. J Hepatol49:821-830, 2008.
56. EspositoE, IaconoA, BiancoG, AutoreG, CuzzocreaS, VajroP, CananiRB, CalignanoA, RasoGM, MeliR: Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr139:905-911, 2009.
57. LiZ, YangS, LinH, HuangJ, WatkinsPA, MoserAB, DesimoneC, SongXY, DiehlAM: Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology37:343-350, 2003.
58. VelayudhamA, DolganiucA, EllisM, PetrasekJ, KodysK, MandrekarP, SzaboG: VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 49:989-997, 2009.
59. LeeHY, ParkJH, SeokSH, BaekMW, KimDJ, LeeKE, PaekKS, LeeY: Human originated bacteria, Lactobacillus rhamnosus PL60, produce conjugated linoleic acid and show anti-obesity effects in dietinduced obese mice. Biochim Biophys Acta1761:736-744, 2006.
60. YadavH, JainS, SinhaPR: Antidiabetic effect of probiotic dahi containing Lactobacillus acidophilus and Lactobacillus casei in high fructose fed rats. Nutrition23:62-68, 2007.
61. WangY, XuN, XiA, AhmedZ, ZhangB, BaiX: Effects of Lactobacillus plantarum MA2 isolated from Tibet kefir on lipid metabolism and intestinal microflora of rats fed on high-cholesterol diet. Appl Microbiol Biotechnol84:341-347, 2009.
62. NardoneG, CompareD, LiguoriE, Di MauroV, RoccoA, BaroneM, NapoliA, LapiD, IoveneMR, ColantuoniA: Protective effects of Lactobacillus paracasei F19 in a rat model of oxidative and metabolic hepatic injury. Am J Physiol Gastrointest Liver Physiol299:G669-G676, 2010.
63. AdawiD, AhrneS, MolinG: Effects of different probiotic strains of Lactobacillus and Bifidobacterium on bacterial translocation and liver injury in an acute liver injury model. Int J Food Microbiol70:213-220, 2001.
64. LamEK, TaiEK, KooMW, WongHP, WuWK, YuL, SoWH, WooPC, ChoCH: Enhancement of gastric mucosal integrity by Lactobacillus rhamnosus GG. Life Sci80:2128-2136, 2007.
65. ForsythCB, FarhadiA, JakateSM, TangY, ShaikhM, KeshavarzianA: Lactobacillus GG treatment ameliorates alcohol- induced intestinal oxidative stress, gut leakiness, and liver injury in a rat model of alcoholic steatohepatitis. Alcohol 43:163-172, 2009.
66. SegawaS, WakitaY, HirataH, WatariJ: Oral administration of heat-killed Lactobacillus brevis SBC8803 ameliorates alcoholic liver disease in ethanol-containing diet-fed C57BL/6N mice. Int J Food Microbiol128:371-377, 2008.
67. LoguercioC, De SimoneT, FedericoA, TerraccianoF, TuccilloC, Di ChiccoM, CarteniM: Gut-liver axis: a new point of attack to treat chronic liver damage?Am J Gastroenterol97:2144-2146, 2002.
68. LoguercioC, FedericoA, TuccilloC, TerraccianoF, D’AuriaMV, De SimoneC, Del Vecchio BlancoC: Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol39:540-543, 2005.
69. StadlbauerV, MookerjeeRP, HodgesS, WrightGA, DaviesNA, JalanR: Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol48:945-951, 2008.
70. LataJ, NovotnyI, PribramskaV, JurankovaJ, FricP, KroupaR, StiburekO: The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol19:1111-1113, 2007.
71. LiuQ, DuanZP, HaDK, BengmarkS, KurtovicJ, RiordanSM: Symbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39:1441-1449, 2004.
72. ZhaoHY, WangHJ, LuZ, XuSZ: Intestinal microflora in patients with liver cirrhosis. Chin J Dig Dis5:64-67, 2004.
73. BajajJS, SaeianK, ChristensenKM, HafeezullahM, VarmaRR, FrancoJ, PleussJA, KrakowerG, HoffmannRG, BinionDG: Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol103:1707-1715, 2008.
74. MalaguarneraM, GrecoF, BaroneG, GarganteMP, ToscanoMA: Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, doubleblind, placebo-controlled study. Dig Dis Sci52:3259-3265, 2007.
75. MalaguarneraM, GarganteMP, MalaguarneraG, SalmeriM, MastrojeniS, RampelloL, PennisiG, Li VoltiG, GalvanoF: Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol22:199-206, 2010.
76. PeregD, KotliroffA, GadothN, HadaryR, LishnerM, Kitay- CohenY: Probiotics for patients with compensated liver cirrhosis: a double-blind placebo-controlled study. Nutrition27:177-181, 2011.